Later stages of Alzheimer's disease and other tauopathies are characterized by the aggregation of altered tau protein, and a toxic surrounding biochemistry that provokes inflammation and destroys neurons. So far little headway has been made towards therapies that can halt tau pathology, by clearing harmful tau or preventing its formation.
Later stages of Alzheimer's disease and other tauopathies are characterized by the aggregation of altered tau protein, and a toxic surrounding biochemistry that provokes inflammation and destroys neurons.
The peptide discussed can only reduce tau pathology in mouse models of tauopathy, not eliminate it.
So far little headway has been made towards therapies that can halt tau pathology, by clearing harmful tau or preventing its formation.
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
Later stages of Alzheimer's disease and other tauopathies are characterized by the aggregation of altered tau protein, and a toxic surrounding biochemistry that provokes inflammation and destroys neurons. So far little headway has been made towards therapies that can halt tau pathology, by clearing harmful tau or preventing its formation. Unfortunately, many discoveries in the neurodegenerative field are approaches that cannot be curative, and this is the case here.
Given the several decade span of intense effort devoted to the clearance of amyloid-ОІ in the brain before success ultimately emerged, we might expect that much more remains to be accomplished in order to reach the same point for tau.
Open the app view to save this story, compare related coverage, and continue from the same source.